GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » Total Equity

Nektar Therapeutics (LTS:0UNL) Total Equity : $48.88 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Nektar Therapeutics Total Equity?

Nektar Therapeutics's total equity for the quarter that ended in Sep. 2024 was $48.88 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Nektar Therapeutics Total Equity Historical Data

The historical data trend for Nektar Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Total Equity Chart

Nektar Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,405.39 1,077.30 679.51 366.64 130.99

Nektar Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 159.37 130.99 126.71 79.69 48.88

Nektar Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nektar Therapeutics's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=398.033-267.046
=130.99

Nektar Therapeutics's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=307.966-259.082
=48.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nektar Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics Business Description

Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

Nektar Therapeutics Headlines

No Headlines